AstraZeneca in Discovery Pact with Cellular Dynamics
Cellular Dynamics International, Inc. (CDI) entered a Center of Excellence agreement with AstraZeneca to accelerate drug discovery efforts using human induced pluripotent stem cell (iPSC) lines and tissue cells.
Cellular Dynamics International, Inc. (CDI) entered a Center of Excellence agreement with AstraZeneca to accelerate drug discovery efforts using human induced pluripotent stem cell (iPSC) lines and tissue cells. Financial terms were not disclosed.
iPSC technology is based on reprogramming adult cells from a blood sample or a skin biopsy to a pluripotent stem cell state and has shown promise in delivering human cell models of high utility in drug discovery, without the ethical concerns linked to the use of human embryonic stem cells.
AZ will utilize CDI’s commercially available iCell and MyCell products for iPSC reprogramming and differentiation, and the two companies will collaborate to develop one or more novel cell types. AstraZeneca will purchase CDI's iCell products, including iCell Cardiomyocytes, iCell Neurons, iCell Endothelial Cells, and iCell Hepatocytes, for use in their safety, discovery, and regenerative medicine programs. Also, CDI will work with AZ to develop new iPSC-derived cell types to enable novel discovery screening applications.
Steve Rees, vice president of Screening Sciences & Sample Management, Discovery Sciences at AZ, said, "This agreement with Cellular Dynamics enables AstraZeneca to access world-leading expertise in stem cell technology so that we can better test potential new medicines for safety and efficacy."
Bob Palay, chief executive officer of CDI, said, "This is the third Center of Excellence agreement we have entered into with a global pharma company, and these partnerships show customer recognition that leveraging CDI's technical expertise and resources can help accelerate their discoveries. We are excited that AstraZeneca shares our vision that iPSC technology can be transformative. The Center of Excellence agreements show CDI's leadership in developing best practices to employ human iPSCs to advance healthcare discoveries."
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.